PureTech Health plc

PRTC

GB00BY2Z0H74

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:22 2024-04-17 am EDT			5-day change	1st Jan Change
209 ^GBX	-0.71%		-3.91%	+7.62%

Apr. 16	EARNINGS AND TRADING: J Smart boosts revenue, Tertiary starts drilling	AN
Apr. 16	PureTech Health plc Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis	CI

PureTech Health plc(LSE:PRTC) added to FTSE 350 (Ex Investment Companies) Index

September 19, 2022 at 12:00 am EDT

PureTech Health plc(LSE:PRTC) added to FTSE 350 (Ex Investment Companies) Index (GBP)

Latest news about PureTech Health plc

EARNINGS AND TRADING: J Smart boosts revenue, Tertiary starts drilling	Apr. 16	AN
PureTech Health plc Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis	Apr. 16	CI
US FDA hands fast track to PureTech head and neck cancer treatment	Apr. 11	AN
PureTech Health plc Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers	Apr. 11	CI
PureTech Health CEO Zohar moves to head-up portfolio firm Seaport	Apr. 09	AN
PureTech Health Names Bharatt Chowrira Chief Executive; Receives $100 Million in Funding for Seaport Therapeutics Startup	Apr. 09	MT
PureTech Health's Seaport Therapeutics Raises $100 Million at Launch	Apr. 09	MT
PureTech Health CEO Steps Down; Successor Named	Apr. 09	MT
PureTech Health plc Announces Chief Executive Officer Changes	Apr. 09	CI
PureTech Health plc Announces Management Changes	Apr. 09	CI
Seaport Therapeutics announced that it has received $100 million in funding from Arch Venture Partners, L.P., Sofinnova Investment, Inc., Third Rock Ventures, LLC, PureTech Health plc	Apr. 08	CI
ADRs End Flat, Ehang Holdings Ltd. Climbs 15.6%	Mar. 19	DJ
European large-caps rise on eve of Fed decision	Mar. 19	AN
Tranche Update on PureTech Health plc's Equity Buyback Plan announced on May 5, 2022.	Mar. 19	CI
PureTech shares jump on USD100 million tender offer proposal	Mar. 19	AN
PureTech Health to Return $100 Million to Shareholders via Tender Offer	Mar. 19	MT
PureTech Health Proposes $100 Million Capital Return	Mar. 19	MT
PureTech Health: Bristol Myers Squibb Wraps Up $14 Billion Acquisition of Karuna	Mar. 18	MT
PureTech Health: Bristol Myers Squibb Wraps Up $14 Billion Acquisition of Karuna	Mar. 18	MT
PureTech Health Says US FDA Grants Orphan Drug Label to LYT-200 to Treat Acute Myeloid Leukemia	Mar. 13	MT
PureTech Health celebrates drug designation for LYT-200 from US FDA	Mar. 13	AN
PureTech Gets FDA Orphan Designation for LYT-200 in Acute Myeloid Leukemia	Mar. 13	DJ
PureTech notes positive results from Shionogi's EndeavorRx ADHD trial	Feb. 27	AN
PureTech Health plc's Equity Buyback announced on May 5, 2022, has closed with 19,429,491 shares, representing 6.88% for $50 million.	Feb. 07	CI
Transcript : PureTech Health plc Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:00 AM	Jan. 10

PureTech Health plc is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has developed 27 therapeutics and therapeutic candidates, including two (Plenity and EndeavorRx) that have received both United States (US) Food and Drug Administration (FDA) clearance and European marketing authorization. The Company's pipeline includes LYT-100, LYT-200, LYT-300, LYT-310 and LYT-503/IMB-150. LYT-100 (deupirfenidone) is being advanced for the potential treatment of conditions involving inflammation and fibrosis. It is developing LYT-200 for the treatment of metastatic/locally advanced solid tumors that have poor survival rates, including urothelial and head and neck cancers. LYT-300 is an oral prodrug of allopregnanolone, which is being advanced for the potential treatment of anxiety disorders and postpartum depression.

Sector

Biotechnology & Medical Research

Calendar

2024-04-24 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for PureTech Health plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.602 USD

Average target price

6.205 USD

Spread / Average Target

+138.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PURETECH HEALTH PLC	+7.62%	707M
IQVIA HOLDINGS INC.	-1.78%	41.71B
LONZA GROUP AG	+47.70%	41.56B
MODERNA, INC.	+4.01%	39.74B
CELLTRION, INC.	-15.14%	25.61B
ICON PUBLIC LIMITED COMPANY	+3.16%	24.26B
ALNYLAM PHARMACEUTICALS, INC.	-24.08%	18.55B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	11.93B
MEDPACE HOLDINGS, INC.	+24.76%	11.93B
UNITED THERAPEUTICS CORPORATION	+7.01%	10.91B

Other Biotechnology & Medical Research